U.S. Markets close in 2 hrs 24 mins

Roche Holding AG (RHHBY)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
34.34-0.09 (-0.26%)
As of 1:18PM EDT. Market open.
People also watch
NVSSNYNSRGYAZNBAYRY
Interactive chart
Previous Close34.43
Open34.43
Bid0.00 x
Ask0.00 x
Day's Range34.29 - 34.47
52 Week Range25.25 - 36.82
Volume378,688
Avg. Volume1,056,270
Market Cap227.03B
Beta0.51
PE Ratio (TTM)24.51
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.03 (3.00%)
Ex-Dividend Date2017-03-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • Benzinga5 hours ago

    The Current State Of The Breast Cancer Treatment Space

    Puma Biotechnology Inc (NASDAQ: PBYI ) popped 88 percent Monday on news that its neratinib candidate , an early-stage breast cancer treatment for human epidermal growth factor receptor-2 (HER2) positive ...

  • Incyte Teams Up With Dow's Merck To Trounce Roche In Cancer
    Investor's Business Daily5 days ago

    Incyte Teams Up With Dow's Merck To Trounce Roche In Cancer

    Incyte stock popped to a month-high Thursday after its immuno-oncology drug proved effective in matchups with Merck's Keytruda and Bristol's Opdivo.

  • Reuters6 days ago

    Merck says test shows Keytruda improves survival for bladder cancer patients

    Pivotal trial results for Merck & Co Inc's immunotherapy drug Keytruda show that it lengthened survival by three months, or nearly 40 percent, for patients with advanced bladder cancer who had stopped responding to chemotherapy. The data, to be presented next month at a meeting of the American Society of Clinical Oncology, follow last week's announcement that rival drug Tecentriq, from Roche Holding AG , did not improve survival when used as a second-line treatment for bladder cancer in a trial. The Merck drug is awaiting U.S. Food and Drug Administration approval, but Tecentriq was approved by the agency last year, contingent on verification of its clinical benefit.